Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377029588> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4377029588 endingPage "A7" @default.
- W4377029588 startingPage "A6.3" @default.
- W4377029588 abstract "Introduction Mucopolysaccharidoses (MPS) are a group of rare lysosomal storage diseases caused by different enzyme deficiencies that lead to accumulation of glycosaminoglycans (GAGs) in lysosomes and the extracellular matrix. This storage-induced inflammation is a key driver of cytopathology in MPS, and pharmacological immunomodulation can improve brain, cartilage and bone symptoms in rodents. As the approved enzyme replacement therapy cannot stop the progression of CNS involvement and several other symptoms, we develop a rational for personalized treatment to address the unmet clinical need in MPS patients. Methods First, we conducted comprehensive literature reviews on MPS type specific inflammatory immune response and on the safety and efficacy of Adalimumab, Infliximab, Abatacept, Alemtuzumab, Anakinra. Second, by expert consensus top candidates for innovative personalized drug repurposing in MPS patients were identified and ranked. Results The key process is the upregulation of toll-like receptor-4 (TLR4) pathway induced by the accumulation of heparan sulfate (HS) in MPS type I, II and III. This and other relevant mech-anisms indicate TNF-alpha and IL-1 as most promising targets. Systematic analysis of the clinical pharmacology of all relevant candidates and several expert focus group meetings identified Anakinra, Adalimumab, Cladribine and Abatacept as top candidate’s dependent on the individual clinical situation. Conclusions These results provide the rational for individual treatment trials (ITTs) with the aim to evaluate immunomodulatory molecules, repurposed in MPS. Furthermore, they will – together with the results of the ITTs – be utilized for the development of a decision tool for the personalized treatment of unmet clinical needs in these patients." @default.
- W4377029588 created "2023-05-19" @default.
- W4377029588 creator A5015179904 @default.
- W4377029588 creator A5059494159 @default.
- W4377029588 creator A5060376569 @default.
- W4377029588 creator A5079734090 @default.
- W4377029588 creator A5079918919 @default.
- W4377029588 creator A5089564343 @default.
- W4377029588 date "2023-05-18" @default.
- W4377029588 modified "2023-09-28" @default.
- W4377029588 title "19 The inflammation in the pathology of patients with mucopolysaccharidosis" @default.
- W4377029588 doi "https://doi.org/10.1136/archdischild-2023-esdppp.19" @default.
- W4377029588 hasPublicationYear "2023" @default.
- W4377029588 type Work @default.
- W4377029588 citedByCount "0" @default.
- W4377029588 crossrefType "journal-article" @default.
- W4377029588 hasAuthorship W4377029588A5015179904 @default.
- W4377029588 hasAuthorship W4377029588A5059494159 @default.
- W4377029588 hasAuthorship W4377029588A5060376569 @default.
- W4377029588 hasAuthorship W4377029588A5079734090 @default.
- W4377029588 hasAuthorship W4377029588A5079918919 @default.
- W4377029588 hasAuthorship W4377029588A5089564343 @default.
- W4377029588 hasBestOaLocation W43770295881 @default.
- W4377029588 hasConcept C126322002 @default.
- W4377029588 hasConcept C17991360 @default.
- W4377029588 hasConcept C203014093 @default.
- W4377029588 hasConcept C2777138892 @default.
- W4377029588 hasConcept C2777226972 @default.
- W4377029588 hasConcept C2777575956 @default.
- W4377029588 hasConcept C2779134260 @default.
- W4377029588 hasConcept C2779338263 @default.
- W4377029588 hasConcept C2779416428 @default.
- W4377029588 hasConcept C2779605438 @default.
- W4377029588 hasConcept C2779969927 @default.
- W4377029588 hasConcept C2780132546 @default.
- W4377029588 hasConcept C2780653079 @default.
- W4377029588 hasConcept C2781228260 @default.
- W4377029588 hasConcept C2910727661 @default.
- W4377029588 hasConcept C60644358 @default.
- W4377029588 hasConcept C71924100 @default.
- W4377029588 hasConcept C86803240 @default.
- W4377029588 hasConceptScore W4377029588C126322002 @default.
- W4377029588 hasConceptScore W4377029588C17991360 @default.
- W4377029588 hasConceptScore W4377029588C203014093 @default.
- W4377029588 hasConceptScore W4377029588C2777138892 @default.
- W4377029588 hasConceptScore W4377029588C2777226972 @default.
- W4377029588 hasConceptScore W4377029588C2777575956 @default.
- W4377029588 hasConceptScore W4377029588C2779134260 @default.
- W4377029588 hasConceptScore W4377029588C2779338263 @default.
- W4377029588 hasConceptScore W4377029588C2779416428 @default.
- W4377029588 hasConceptScore W4377029588C2779605438 @default.
- W4377029588 hasConceptScore W4377029588C2779969927 @default.
- W4377029588 hasConceptScore W4377029588C2780132546 @default.
- W4377029588 hasConceptScore W4377029588C2780653079 @default.
- W4377029588 hasConceptScore W4377029588C2781228260 @default.
- W4377029588 hasConceptScore W4377029588C2910727661 @default.
- W4377029588 hasConceptScore W4377029588C60644358 @default.
- W4377029588 hasConceptScore W4377029588C71924100 @default.
- W4377029588 hasConceptScore W4377029588C86803240 @default.
- W4377029588 hasIssue "6" @default.
- W4377029588 hasLocation W43770295881 @default.
- W4377029588 hasOpenAccess W4377029588 @default.
- W4377029588 hasPrimaryLocation W43770295881 @default.
- W4377029588 hasRelatedWork W1997007445 @default.
- W4377029588 hasRelatedWork W1999498294 @default.
- W4377029588 hasRelatedWork W2018018989 @default.
- W4377029588 hasRelatedWork W2098267476 @default.
- W4377029588 hasRelatedWork W2102240928 @default.
- W4377029588 hasRelatedWork W2115908015 @default.
- W4377029588 hasRelatedWork W2322893822 @default.
- W4377029588 hasRelatedWork W2334277539 @default.
- W4377029588 hasRelatedWork W2486776082 @default.
- W4377029588 hasRelatedWork W4377029588 @default.
- W4377029588 hasVolume "108" @default.
- W4377029588 isParatext "false" @default.
- W4377029588 isRetracted "false" @default.
- W4377029588 workType "article" @default.